Detail of "93413-69-5"

Reference

Differentiating antidepressants of the future: Efficacy and safety

All Rights Reserved. Differentiating antidepressants of the future: Efficacy and safety. Rosenzweig-Lipson, Sharon; Beyer, Chad E.; Hughes, Zoe A.; Khawaja, Xavier; Rajarao, Somana J.; Malberg, Jessica E.; Rahman, Zia; Ring, Robert H.; Schechter, Lee E. (Depression and Anxiety, Wyeth Discovery Neuroscience, Princeton, NJ 08543, USA). Pharmacology & Therapeutics, 113(1), 134-153 (English) 2007 Elsevier B.V. CODEN: PHTHDT. ISSN: 0163-7258.Several reagents with their cas registry numbers 93413-69-5 and 116539-59-4 are used here. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. There have been significant advances in the treatment of depression since the serendipitous discovery that modulating monoaminergic neurotransmission may be a pathol. underpinning of the disease. Despite these advances, particularly over the last 15 years with the introduction of selective serotonin and/or norepinephrine reuptake inhibitors (SNRI), there still remain multiple unmet clin. needs that would represent substantial improvements to current treatment regimens. In terms of efficacy there have been improvements in the percentage of patients achieving remission but this can still be dramatically improved and, in fact, issues still remain with relapse. Furthermore, advances are still required in terms of improving the onset of efficacy as well as addressing the large proportion of patients who remain treatment resistant. While this is not well understood, collective research in the area suggests the disease is heterogeneous in terms of the multiple parameters related to etiol., pathol. and response to pharmacol. agents. In addn. to efficacy further therapeutic advances will also need to address such issues as cognitive impairment, pain, sexual dysfunction, nausea and emesis, wt. gain and potential cardiovascular effects. With these unmet needs in mind, the next generation of antidepressants will need to differentiate themselves from the current array of therapeutics for depression. There are multiple strategies for addressing unmet needs that are currently being investigated. These range from combination monoaminergic approaches to subtype selective agents to novel targets that include mechanisms to modulate neuropeptides and excitatory amino acids (EAA). This review will discuss the many facets of differentiation and potential strategies for the development of novel antidepressants. .

Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR

All Rights Reserved. Using meta-regression in performing indirect-comparisons: comparing escitalopram with venlafaxine XR. Eckert, Laurent; Falissard, Bruno (Inserm, U669, Paris, Fr.). Current Medical Research and Opinion, 22(11), 2313-2321 (English) 2006 LibraPharm Ltd. CODEN: CMROCX. ISSN: 0300-7995. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Background: In the absence of well-powered, randomized, direct-comparison trials, indirect comparisons are the only option for comparing treatment strategies. Several methodologies have been developed and each has sparked criticism. Using direct comparisons of escitalopram vs. venlafaxine extended release (XR), we explore the differences between the two compds. through indirect comparisons. Methods: The CENTRAL, Medline and Embase databases were interrogated, focusing on randomized placebo-controlled clin. trials involving adult patients treated for major depressive disorder in the acute phase. Corresponding authors were contacted to reduce missing data. Effect sizes were derived from each study's primary outcome. For indirect comparisons, a global effect size was computed through meta-regression. For direct comparisons, the studies were considered sep. due to missing data. Non-inferiority assessments were employed. The conclusion of the meta-regression was then compared with the conclusions made in direct comparison trials. Results: Ten placebo-controlled studies - six assessing escitalopram and four assessing venlafaxine XR - and two direct comparison studies were retrieved. Escitalopram was found to be non-inferior to venlafaxine XR in both indirect and direct comparisons with results of mean -0.02 (unilateral 95% confidence interval [CI] -0.16 to ￥) and 0. 93413-69-5 and 128196-01-0 which are cas registry numbers of chemicals are mentioned.23 (95% CI -0.01 to ￥), resp. Results obtained by both indirect and direct comparisons were similar. Investigating the influence of age, gender repartition and severity at baseline suggests that results are consistent. Results were also considered robust against publication bias. Conclusions: This empirical finding suggests that escitalopram is non-inferior to venlafaxine XR. This reinforces the evidence found in direct comparisons trials. Indirect comparisons through meta-regression may be suitable to support decision-making. To fully assess its potential, further evaluation of this methodol., using other examples, is needed. .